X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah, U.S., on Wednesday, Aug. 31, 2016. A Nov. 2015 forecast from health data firm IMS Health expects global sales of brand and generic prescription drugs, and nonprescription medicines, to total $1.4 trillion in 2020. Photographer: George Frey/Bloomberg Bottles of Purdue Pharma OxyContin medication sit on a pharmacy shelf in Provo, Utah, on Aug. 31, 2016. A November 2015 forecast from health data firm IMS Health expects global sales of brand and generic prescription drugs, and nonprescription medicines, to total $1.4 trillion in 2020. Photographer: George Frey/Bloomberg

Purdue Pharma’s proposed settlement on Wednesday could provide some assurances about compensation for cities and counties with pending lawsuits, in the likely event that the opioid manufacturer files for bankruptcy, experts say. But several state attorneys general still balked at the deal as inadequate.

The settlement’s details remain unclear, but some reports have indicated that the Sackler family, who founded Purdue, would provide $3 billion over seven years, and that another $7 billion to $9 billion could come from future sales of OxyContin, its prescription opiate, as well as drugs designed to treat opioid addiction. The deal reportedly resolves the claims of about 2,500 cities and counties, plus half the states.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Amanda Bronstad

Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Critical Mass. She is based in Los Angeles.

More from this author

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

Defending Federal Criminal Cases: Attacking the Government's ProofBook

Equips defense attorneys with the legal arguments and tactics they can and should use to challenge the government's evidence at every stage of a criminal case.

Get More Information
 

Elite Trial Lawyers 2021Event

The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.

Get More Information
 

The British Legal Awards 2021Event

Celebrating achievement, excellence, and innovation in the legal profession in the UK.

Get More Information
 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.